Androgens
Androgens used for testosterone replacement therapy organized by route of administration chart.
Hypogonadism
Diagnosis and Management of Pituitary Incidentaloma
Patient evaluation, follow-up testing, and treatment differ based on lesion size and presence of hormone abnormalities with pituitary incidentalomas.
Nasal Gel Increases Testosterone, Maintains Semen Parameters
In a study, most symptomatic hypogonadal men treated with Natesto, a short-acting 4.5% nasal testosterone gel, attained normal testosterone levels at 6 months while preserving sperm counts.
First Testosterone Undecanoate Softgel Approved by FDA for Hypogonadism
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
ACP Issues Guidelines for Use of Testosterone Therapy in Age-Related Low Testosterone
The American College of Physicians has issued a set of recommendations to clarify the potential benefits and harms of testosterone therapy in men with age-related low testosterone.
Waist Circumference Affects Coronary Plaque Accumulation in Testosterone Therapy
Older men receiving testosterone treatment with higher waist-to-hip ratio experience greater increases in noncalcified coronary plaque volume.
Short-Term Testosterone Therapy Associated With VTE Risk in Men
For men with and without hypogonadism, testosterone therapy is associated with an increased short-term risk for venous thromboembolism.
Suboptimal Screening for Hypogonadism in Men Receiving Opioids
More men with long-term opioid use are screened for low testosterone than men taking opioids for a short period of time; however, given the known link between opioid use and low testosterone, these rates were still lower than expected.
Managing Opioid-Induced Androgen Deficiency
The increased opioid use has been associated with a rising incidence of opioid-induced endocrinopathy, most commonly in the form of androgen deficiency.
Testosterone Undecanoate May Reduce CV Morbidity, Mortality in Men With Hypogonadism, Type 2 Diabetes
Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular morbidity and mortality in patients with hypogonadism and type 2 diabetes.
-
Loading...
-
Loading...
Next post in ADA 79th Scientific Sessions 2019
